

Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022

<https://marketpublishers.com/r/P263B37C73CEN.html>

Date: September 2012

Pages: 187

Price: US\$ 2,635.00 (Single User License)

ID: P263B37C73CEN

Abstracts

New study shows you commercial prospects for leading biopharmaceutical companies

How are companies in the biological medicines (biologics) industry performing? Visiongain's new report shows you organisations' prospects to 2022. There you find financial data, trends, opportunities and commercial potentials.

We assess 20 leading developers and producers of biological drugs and vaccines - our analyses help you see the future of the biopharma industry and market. See how sales can increase.

In our investigation you discover a biologics revenue forecast for each company, growth rates, rankings and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 113 tables and 80 charts.

Our work lets you assess the most lucrative areas of the biologicals market, especially 20 companies at the forefront of biopharmaceuticals. Their technologies hold great promise.

You can stay ahead in knowledge. The following sections highlight what you find in the report.

The leading company - you find prospects to 2022 for Roche

Roche is the first company our study analyses. See information on its products and activities in 2012, looking ahead.

You find discussions and analysis of its product portfolio:

Rituxan

Avastin

Herceptin

Lucentis

Pegasys and other agents.

Also you investigate Roche's R&D pipeline, its commercial challenges from 2012 and a forecast of its biologics revenue to 2022. Next, our report covers many other companies.

You see prospects for leading pharmaceutical biotechs and specialist manufacturers

Our report gives you profiles and analyses for many other companies, including biopharmaceutical specialists such as these:

Sanofi

Novo Nordisk

Pfizer

GlaxoSmithKline (GSK)

Merck & Co.

Novartis

Amgen

Biogen Idec

CSL Behring

Grifols

Allergan.

You examine product portfolios, breakdowns of sales, R&D pipelines and outlooks, including biologics revenue forecasts to 2022. Our study also covers vaccines. You find analyses of competition, as well as commercial drivers and restraints for those companies and others.

You discover prospects for other leading developers and manufacturers of biological drugs

Our investigation shows you prospects for other biological medicine producers, including revenue forecasts to 2022 with discussions.

See prospects for other leading European companies:

Merck KGaA

Bayer

AstraZeneca.

See prospects for other leading US companies:

Johnson & Johnson (J&J)

Abbott Laboratories

Baxter

Eli Lilly

Bristol-Myers Squibb (BMS).

This decade many opportunities will arise for large entities and specialty healthcare firms. See outlooks and revenue forecasts for the top 20 players. In our work you assess R&D and other issues influencing future results.

You investigate what affects companies and their market, seeing its revenue prospects too

Our report also analyses and discusses the overall market for biological drugs and vaccines. You see what influences the biopharma sector from 2012:

Competition, collaborations, technology and product licensing

Corporations, mergers and acquisitions (M&A deals - e.g. GSK and Human Genome Sciences in summer 2012)

R&D - immunotherapies, plasma agents, hormones and other proteins and recombinant molecules, including cellular therapies

Opportunities in treating cancers, CNS disorders, inflammatory diseases, viral infections, blood ailments, diabetes, eye diseases and other medical conditions

Strengths, weaknesses, opportunities and threats, including the entry of biosimilars and follow-on protein products.

There you investigate prospects for therapeutic proteins, monoclonal antibodies (mAbs), vaccines, fusion proteins and other biotechnological medicines. See what the future holds.

You also assess biological therapies by overall world market and product class (five submarkets), seeing forecasted revenues, sales shares and growth rates to 2022.

The biologics segment is growing faster than the overall world pharmaceutical market, a trend that will continue, our analyses predict. From 2012, biologic blockbusters will fill many of the top sales places. Also, most of those products will continue revenue growth.

Seven ways Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 helps you

In particular, our report gives you the following knowledge on producers of biologics:

Profiles of 20 leading companies - discover products, recent results, sales breakdowns, strategies, competition and outlooks

Forecasted revenues to 2022 for the 20 leading companies - analyse predicted financial results for each company

Potential revenues to 2022 for the overall world market and 5 biological product submarkets - find the biopharma industry's sales prospects

Review of R&D pipelines - investigate developmental trends and progress

Investigation of competition and opportunities influencing biomedical sales

Discussion of what stimulates and restrains companies, the industry and the market

Prospects for established businesses and firms entering biopharma.

That work gives you quantitative and qualitative analyses with independent predictions. You receive information found only in our investigation.

There you find business intelligence to help you understand the future of the biologicals industry and market. You see where prospects are lucrative, where growth is likely.

With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses, saving you time too.

You see prospects for biologics manufacturers by ordering now

Visiongain's study is for everybody needing commercial analysis of healthcare biotechnology. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government

Contents

1. EXECUTIVE SUMMARY

- 1.1 Leading Biological Drug Manufacturers: Overview of Findings
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods
- 1.4 Scope of this Report
 - 1.4.1 Drugs Considered for this Report

2. OVERVIEW OF THE WORLD BIOLOGICALS MARKET, 2012-2022

- 2.1 Biological Drugs
 - 2.1.1 Defining the Field
- 2.2 The Biological Drugs Market, 2011
- 2.3 Leading Classes of Biological Drug
 - 2.3.1 Therapeutic Proteins
 - 2.3.2 Monoclonal Antibodies (MAbs)
 - 2.3.3 Vaccines
 - 2.3.4 Fusion Proteins
 - 2.3.5 Other Biological Drugs
- 2.4 The Biological Drugs Market: Overall Revenue Forecast, 2012-2022
- 2.5. The Biological Drugs Market: Drivers and Restraints, 2012
- 2.6 Leading 20 Biological Drug Manufacturers, 2011

3. THE LEADING BIOLOGICS MANUFACTURER: ROCHE, 2012-2022

- 3.1 Roche Biologics in 2012: Overview
- 3.2 Roche Biologics Portfolio, 2012
 - 3.2.1 Rituxan (rituximab)
 - 3.2.2 Avastin (bevacizumab)
 - 3.2.3 Herceptin (trastuzumab)
 - 3.2.4 Lucentis (ranibizumab)
 - 3.2.5 Pegasys (pegylated interferon alpha 2a)
 - 3.2.6 Other Roche Biologics
- 3.3 Roche Biologics Pipeline, 2012
 - 3.3.1 Obinituzumab (RG7159, GA101)
 - 3.3.2 Onartuzumab (MetMAb, RG3638)
 - 3.3.3 Trastuzumab emtansine (T-DM1, RG3502)

- 3.3.4 Ocrelizumab (RG1594)
- 3.3.5 Lebrikizumab
- 3.3.6 Gantenerumab (RG1450)
- 3.4 Drivers and Restraints for Roche Biologics, 2012
- 3.5 Roche Biologics Revenue Forecast, 2012-2022

4. BIOTECHS AND SPECIALIST MANUFACTURERS, 2012-2022

- 4.1 Amgen, 2012
 - 4.1.1 Amgen Biologics in 2012: Overview
 - 4.1.2 Amgen Biologics Portfolio, 2012
 - 4.1.2.1 Enbrel (etanercept)
 - 4.1.2.2 Neulasta/Neupogen (pegfilgrastim/filgrastim)
 - 4.1.2.3 Epogen (epoetin alpha)/ Aranesp (darbepoietin alpha)
 - 4.1.2.4 Other Amgen Biologics
 - 4.1.3 Amgen's Biologics Pipeline, 2012
 - 4.1.3.1 AMG386
 - 4.1.3.2 Ganitumab (AMG 479)
 - 4.1.3.3 Talimogene Laherparepvec
 - 4.1.3.4 AMG145
 - 4.1.3.5 AMG785
 - 4.1.4 Amgen Drivers and Restraints, 2012
 - 4.1.5 Amgen Biologics Revenue Forecast, 2012-2022
- 4.2 Biogen Idec, 2012
 - 4.2.1 Biogen Idec Biologics in 2012: Overview
 - 4.2.2 Biogen Idec's Product Portfolio, 2012
 - 4.2.2.1 Avonex (beta-interferon 1a)
 - 4.2.2.2 Tysabri (natalizumab)
 - 4.2.3 Biogen Idec's Biologics Pipeline, 2012
 - 4.2.3.1 PEG-interferon beta-1a (BIIB 017)
 - 4.2.3.2 Recombinant Factor VIII-Fc and Factor IX-Fc
 - 4.2.3.3 Galiximab
 - 4.2.4 Biogen Idec Drivers and Restraints, 2012
 - 4.2.5 Biogen Idec Biologics Revenue Forecast, 2012-2022
- 4.3 CSL Behring, 2012
 - 4.3.1 CSL Behring Biologics in 2012: Overview
 - 4.3.2 CSL's Product Portfolio, 2012
 - 4.3.2.1 Immunoglobulins
 - 4.3.2.2 Plasma-Derived Coagulants

- 4.3.2.3 Helixate
- 4.3.2.4 Albumin
- 4.3.3 CSL's Biologics Pipeline, 2012
 - 4.3.3.1 Overview of New Products
- 4.3.4 Drivers and Restraints for CSL
- 4.3.5 CSL Biologics Revenue Forecast, 2012-2022
- 4.4 Grifols, 2012
 - 4.4.1 Grifols Biologics in 2012: Overview
 - 4.4.2 Grifols' Product Portfolio, 2012
 - 4.4.2.1 Gamunex/Gamunex-C (Immune Globulin Injection, 10% Caprylate/Chromatography Purified)
 - 4.4.2.2 Prolastin/ Prolastin-C (Alpha-1 Proteinase Inhibitor)
 - 4.4.2.3 Fraction VIII (Koate DVI)
 - 4.4.3 Grifols' Biologics Pipeline, 2012
 - 4.4.3.1 Plasma-Derived and Recombinant Plasmins
 - 4.4.4 Drivers and Restraints for Grifols Biologics, 2012
 - 4.4.5 Market Forecast for Grifols Biologics, 2012-2022
- 4.5 Allergan, 2012
 - 4.5.1 Allergan Biologics: Overview, 2012
 - 4.5.2 Allergan Product Portfolio, 2012
 - 4.5.3 Allergan Biologics Pipeline: Overview, 2012
 - 4.5.4 Drivers and Restraints for Allergan Biologics, 2012
 - 4.5.5 Market Forecast for Allergan Biologics, 2012-2022

5. LEADING VACCINES MANUFACTURERS, 2012-2022

- 5.1 Sanofi, 2012
 - 5.1.1 Sanofi Biologics: Overview, 2012
 - 5.1.2 Sanofi Biologics Portfolio, 2012
 - 5.1.2.1 Lantus (insulin glargine)
 - 5.1.2.2 Genzyme Legacy Products
 - 5.1.2.3 Polio/Pertussis/Hib Vaccines
 - 5.1.2.4 Influenza Vaccines
 - 5.1.2.5 Other Sanofi Biologics
 - 5.1.3 Sanofi Biologics Pipeline, 2012
 - 5.1.3.1 Hexaxim (DTP-HepB-Polio-Hib Vaccine)
 - 5.1.3.2 Dengue Fever Vaccine
 - 5.1.3.3 Zaltrap (aflibercept)
 - 5.1.3.4 Sarilumab

- 5.1.4 Drivers and Restraints for Sanofi Biologics, 2012
- 5.1.5 Market Forecast for Sanofi Biologics, 2012-2022
- 5.2 Pfizer, 2012
 - 5.2.1 Pfizer Biologics: Overview, 2012
 - 5.2.2 Pfizer Biologics Portfolio, 2012
 - 5.2.2.1 Prevnar-13/Prevnar-7 (Pneumococcal 13-Valent/ 7-Valent Conjugate Vaccine)
 - 5.2.3 Pfizer Biologics Pipeline, 2012
 - 5.2.3.1 Inotuzumab Ozogamicin
 - 5.2.3.2 Fezakinumab
 - 5.2.3.3 Ozoralizumab
 - 5.2.3.4 Tanezumab (RN624)
 - 5.2.4 Drivers and Restraints for Pfizer Biologics
 - 5.2.5 Market Forecast for Pfizer Biologics, 2012-2022
- 5.3 GlaxoSmithKline, 2012
 - 5.3.1 GlaxoSmithKline Biologics: Overview, 2012
 - 5.3.2 GlaxoSmithKline Biologics Portfolio, 2012
 - 5.3.2.1 Infanrix/Pediarix
 - 5.3.2.2 Hepatitis Vaccines
 - 5.3.2.3 Cervarix
 - 5.3.2.4 Synflorix
 - 5.3.2.5 Other GlaxoSmithKline Biologics, 2012
 - 5.3.3 GlaxoSmithKline Biologics Pipeline, 2012
 - 5.3.3.1 Astuprotimut (MAGE-A3 Therapeutic Vaccine)
 - 5.3.3.2 Menhibrix (Meningitis C and Y and Hib Vaccine)
 - 5.3.3.3 GSK1437173A (Varicella Zoster Virus Vaccine)
 - 5.3.3.4 Mosquirix
 - 5.3.3.5 Nimenrix
 - 5.3.4 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
 - 5.3.5 Market Forecast for GlaxoSmithKline, 2012-2022
- 5.4 Merck & Co., 2012
 - 5.4.1 Merck Biologics: Overview, 2012
 - 5.4.2 Merck Biologics Portfolio: Overview, 2012
 - 5.4.2.1 Gardasil
 - 5.4.2.2 ProQuad/ MMR-II/ Varivax
 - 5.4.2.3 PegIntron (peginterferon alpha-2b)
 - 5.4.2.4 RotaTeq
 - 5.4.2.5 Other Merck Biologics, 2012
 - 5.4.3 Merck Biologics Pipeline, 2012

5.4.3.1 V503

5.4.3.2 V212

5.4.3.3 Allergy Vaccines

5.4.3.4 MK-0646

5.4.4 Drivers and Restraints for Merck Biologics, 2012

5.4.5 Market Forecast for Merck Biologics, 2012-2022

5.5 Novartis, 2012

5.5.1 Novartis Biologics: Overview, 2012

5.5.2 Novartis Biologics Portfolio, 2012

5.5.2.1 Novartis Vaccines

5.5.3 Novartis Biologics Pipeline, 2012

5.5.3.1 Bexsero

5.5.4 Drivers and Restraints for Novartis Biologics, 2012

5.5.5 Market Forecast for Novartis Biologics, 2012-2022

6. LEADING EUROPEAN BIOLOGICS MANUFACTURERS, 2012-2022

6.1 Novo Nordisk, 2012

6.1.1 Novo Nordisk Biologics: Overview, 2012

6.1.2 Novo Nordisk's Biologics Portfolio, 2012

6.1.2.1 NovoRapid/ NovoLog (insulin aspart)

6.1.2.2 NovoSeven (eptacog alpha)

6.1.2.3 Levemir (insulin detemir)

6.1.2.4 Norditropin (Somatropin Injection)

6.1.3 Novo Nordisk's Biologics Pipeline, 2012

6.1.3.1 Tresiba (Insulin Degludec)

6.1.3.2 Catridecacog

6.1.3.3 NN7008

6.1.4 Drivers and Restraints for Novo Nordisk

6.1.5 Market Forecast for Novo Nordisk Biologics, 2012-2022

6.2 Merck KGaA

6.2.1 Merck KGaA Biologics: Overview

6.2.2 Merck KGaA Portfolio, 2012

6.2.2.1 Rebif (interferon beta-1a)

6.2.2.2 Erbitux (cetuximab)

6.2.3 Merck KGaA Pipeline, 2012

6.2.3.1 Atacicept (TACI-Ig)

6.2.3.2 Adecatumumab

6.2.3.3 Stimuvax (emepepimut-S)

6.2.3.4 SEED Bodies

6.2.4 Drivers and Restraints for Merck KGaA

6.2.5. Market Forecast for Merck KGaA

6.3 Bayer

6.3.1 Bayer Biologics: Overview, 2012

6.3.2 Bayer Biologics Portfolio, 2012

6.3.2.1 Betaferon (interferon beta-1b)

6.3.2.2 Kogenate (recombinant Factor VIII)

6.3.2.3 Eylea (afibercept)

6.3.3 Bayer Pipeline, 2012

6.3.3.1 L19-131I

6.3.3.2 L19-TNF

6.3.3.3 BAY 94-9027

6.3.4 Drivers and Restraints for Bayer Biologics, 2012

6.3.5 Market Forecast for Bayer Biologics, 2012-2022

6.4 AstraZeneca

6.4.1 AstraZeneca Biologics Overview, 2012

6.4.2 AstraZeneca Biologics Portfolio, 2012

6.4.2.1 Synagis (palivizumab)

6.4.3 AstraZeneca Biologics Pipeline, 2012

6.4.4 AstraZeneca Biologics Drivers and Restraints, 2012

6.4.5 AstraZeneca Market Forecast, 2012-2022

7. LEADING US BIOLOGICS MANUFACTURERS, 2012-2022

7.1 Johnson & Johnson

7.1.1 Johnson & Johnson Biologics: Overview, 2012

7.1.2 Johnson & Johnson Biologics Portfolio

7.1.2.1 Remicade (infliximab)

7.1.2.2 Stelara (ustekinumab)

7.1.2.3 Other Johnson & Johnson Biologics

7.1.3 Johnson & Johnson Biologics Pipeline

7.1.3.1 Bapineuzumab

7.1.3.2 Fulranumab

7.1.3.3 CNTO 328 (siltuximab)

7.1.4 Johnson & Johnson Biologics Drivers and Restraints, 2012

7.1.5 Johnson & Johnson Market Forecast, 2012-2022

7.2 Abbott Laboratories

7.2.1 Abbott Laboratories Biologics: Overview, 2012

- 7.2.2 Abbott Laboratories Biologics Portfolio, 2012
 - 7.2.2.1 Humira (adalimumab)
- 7.2.3 Abbott Laboratories Biologics Pipeline, 2012
 - 7.2.3.1 Daclizumab
- 7.2.4 Abbott Laboratories Biologics Drivers and Restraints, 2012
- 7.2.5 Abbott Laboratories Biologics Market Forecast, 2012-2022
- 7.3 Baxter
 - 7.3.1 Baxter Biologics: Overview, 2012
 - 7.3.2 Baxter Biologics Portfolio, 2012
 - 7.3.2.1 Recombinants
 - 7.3.2.2 Other Areas
 - 7.3.3 Baxter Biologics Pipeline, 2012
 - 7.3.3.1 BAX111 (Recombinant von Willebrand Factor)
 - 7.3.3.2 Adult Autologous Stem Cell Therapy
 - 7.3.3.3 KUR-211 (Growth Factor)
 - 7.3.4 Baxter Biologics Drivers and Restraints, 2012
 - 7.3.5 Baxter Biologics Market Forecast, 2012-2022
- 7.4 Eli Lilly, 2012
 - 7.4.1 Eli Lilly Biologics: Overview, 2012
 - 7.4.2 Eli Lilly Biologics Portfolio, 2012
 - 7.4.2.1 Humalog(insulin lispro)
 - 7.4.2.2 Humulin
 - 7.4.3 Eli Lilly Biologics Pipeline, 2012
 - 7.4.3.1 Liprotamase (Enzyme Replacement Therapy)
 - 7.4.3.2 Solanezumab
 - 7.4.3.3 Necitumumab
 - 7.4.3.4 Ramacicrumab
 - 7.4.3.5 GLP1 FC Fusion Protein
 - 7.4.3.6 Tabalumab
 - 7.4.4 Eli Lilly Biologics Drivers and Restraints, 2012
 - 7.4.5 Eli Lilly Biologics Market Forecast, 2012-2022
- 7.5 Bristol-Myers Squibb, 2012
 - 7.5.1 Bristol-Myers Squibb Biologics: Overview, 2012
 - 7.5.2 Bristol-Myers Squibb Biologics Portfolio, 2012
 - 7.5.2.1 Orencia (abatacept)
 - 7.5.2.2 Other Bristol-Myers Squibb Biologics
 - 7.5.3 Bristol-Myers Squibb Biologics Pipeline, 2012
 - 7.5.3.1 Elotuzumab
 - 7.5.3.2 Anti-PD1 MAb (BMS-936558)

7.5.4 Bristol-Myers Squibb Biologics Drivers and Restraints, 2012

7.5.5 Bristol-Myers Squibb Biologics Market Forecast, 2012-2022

List Of Tables

LIST OF TABLES

- Table 1.1 Currency Exchange Rates, 2011
- Table 2.2 Biological Drugs Market by Class, Revenues (\$bn), Market Share (%), 2011
- Table 2.3 Therapeutic Proteins: Role in the Biological Drugs Market, 2011
- Table 2.4 MAbs: Role in the Biological Drugs Market, 2011
- Table 2.5 Vaccines: Role in the Biological Drugs Market, 2011
- Table 2.6 Fusion Proteins: Role in the Biological Drugs Market, 2011
- Table 2.7 Other Biologics: Role in the Biological Drugs Market, 2011
- Table 2.8 Biological Drugs Market by Class: Revenues (\$bn), Market Share (%), CAGR (%), 2011, 2016, 2022
- Table 2.9 Top 20 Biological Manufacturers: Revenue (\$bn), Market Share (%), 2011
- Table 3.1 Roche: Key Facts, 2012
- Table 3.2 Roche: Leading Biologics, Revenues (\$bn), Share of Biologics Revenue (%), 2011
- Table 3.3 Roche: Selected Pipeline Biologics, Phase II and III, 2012
- Table 3.4 Roche: Selected Pipeline Biologics, Phase I, 2012
- Table 3.5 Roche Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016
- Table 3.6 Roche Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022
- Table 4.1 Amgen: Key Facts, 2012
- Table 4.2 Amgen: Key M&A Deals, 2012
- Table 4.3 Amgen: Lead Biologics Revenues (\$bn), Share of Biologics Revenue (%), 2011
- Table 4.4 Amgen: Selected Pipeline Biologics, 2012
- Table 4.5 Amgen: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016
- Table 4.6 Amgen: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022
- Table 4.7 Biogen Idec: Key Facts, 2012
- Table 4.8 Biogen Idec: Ongoing Collaborations, 2012
- Table 4.9 Biogen Idec: Lead Biologics Revenues (\$bn), Share of Biologics Revenue (%), 2011
- Table 4.10 Biogen Idec: Selected Pipeline Biologics, 2012
- Table 4.11 Biogen Idec: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016
- Table 4.12 Biogen Idec: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022
- Table 4.13 CSL Behring: Key Facts, 2012
- Table 4.14 CSL: Shares of Company's Biologics Revenue (%), 2011
- Table 4.15 CSL: Selected Pipeline Biologics, 2012
- Table 4.16 CSL: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 4.17 CSL: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 4.18 Grifols: Key Facts, 2012

Table 4.19 Grifols: Selected Biologics, Revenues (\$bn), 2010

Table 4.20 Grifols: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 4.21 Grifols: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 4.22 Allergan: Key Facts, 2012

Table 4.23 FDA-Approved On-Label Uses of Botox with Approval Date, 2012

Table 4.24 Allergan: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 4.25 Allergan: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 5.1 Sanofi: Key Facts, 2012

Table 5.2 Sanofi: Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 5.3 Sanofi: Selected Phase III Pipeline Biologics, 2012

Table 5.4 Sanofi: Selected Phase I and Phase II Pipeline Biologics, 2012

Table 5.5 Sanofi: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 5.6 Sanofi: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 5.7 Pfizer: Key Facts, 2012

Table 5.8 Pfizer: Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 5.9 Pfizer: Selected Phase III and Phase II Pipeline, 2012

Table 5.10 Pfizer: Selected Early-Stage Pipeline, 2012

Table 5.11 Pfizer: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 5.12 Pfizer: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 5.13 GlaxoSmithKline: Key Facts, 2012

Table 5.14 GlaxoSmithKline: Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 5.15 GlaxoSmithKline: Selected Late-Stage Pipeline, 2012

Table 5.16 GlaxoSmithKline: Selected Phase I and Phase II Pipeline, 2012

Table 5.17 GlaxoSmithKline: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 5.18 GlaxoSmithKline: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 5.19 Merck: Key Facts, 2012

Table 5.20 Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 5.21 Merck: Selected Pipeline Biologics, 2012

Table 5.22 Merck: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 5.23 Merck: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 5.24 Novartis: Key Facts, 2012

Table 5.25 Leading Novartis Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 5.26 Novartis: Selected Pipeline Biologics, 2012

Table 5.27 Novartis: Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 5.28 Novartis: Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 6.1 Novo Nordisk: Key Facts, 2012

Table 6.2 Novo Nordisk Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 6.3 Novo Nordisk: Selected Pipeline Biologics, 2012

Table 6.4 Novo Nordisk Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 6.5 Novo Nordisk Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 6.6 Merck KGaA: Key Facts, 2012

Table 6.7 Merck KGaA Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 6.8 Merck KGaA Selected Pipeline, 2012

Table 6.9 Merck KGaA Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 6.10 Merck KGaA Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 6.11 Bayer: Key Facts, 2012

Table 6.12 Bayer Leading Biologics, Revenues (\$bn), Share of Revenues (%), 2011

Table 6.13 Bayer Selected Pipeline, 2012

Table 6.14 Bayer Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 6.15 Bayer Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 6.16 AstraZeneca: Key Facts, 2012

Table 6.17 AstraZeneca: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 6.18 AstraZeneca: Selected Biologics Pipeline, 2012

Table 6.19 AstraZeneca Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 6.20 AstraZeneca Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 7.1 Johnson & Johnson: Key Facts, 2012

Table 7.2 Johnson & Johnson: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 7.3 Johnson & Johnson Selected Pipeline, 2011

Table 7.4 Johnson & Johnson Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 7.5 Johnson & Johnson Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 7.6 Abbott Laboratories: Key Facts, 2012

Table 7.7 Abbott: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 7.8 Abbott: Selected Pipeline, 2012

Table 7.9 Abbott Laboratories Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 7.10 Abbott Laboratories Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 7.11 Baxter: Key Facts, 2012

Table 7.12 Baxter: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 7.13 Baxter: Selected Pipeline, 2012

Table 7.14 Baxter Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 7.15 Baxter Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 7.16 Eli Lilly: Key Facts, 2012

Table 7.17 Eli Lilly: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 7.18 Eli Lilly: Selected Biologics Pipeline, 2012

Table 7.19 Eli Lilly Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 7.20 Eli Lilly Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

Table 7.21 Bristol-Myers Squibb: Key Facts, 2012

Table 7.22 Bristol-Myers Squibb: Leading Biologics, Revenues (\$bn), Share of Total Revenues (%), 2011

Table 7.23 Bristol-Myers Squibb: Selected Biologics Pipeline, 2012

Table 7.24 Bristol-Myers Squibb Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2011-2016

Table 7.25 Bristol-Myers Squibb Biologics, Market Forecast (\$bn, AGR %, CAGR %), 2017-2022

List Of Figures

LIST OF FIGURES

- Figure 2.1 Biological Drugs Market by Class, Market Share (%), 2011
- Figure 2.2 Biological Drugs Market by Class: Revenues (\$bn), 2011, 2016, 2022
- Figure 2.3 Biological Drugs Market: Drivers and Restraints, 2012-2022
- Figure 2.4 Top 20 Biological Manufacturers: Market Share (%), 2011
- Figure 3.1 Regional Distribution of Roche Sales (%), 2011
- Figure 3.2 Roche: Leading Biologics, Share of Total Revenues (%), 2011
- Figure 3.3 Drivers and Restraints for Roche Biologics, 2012
- Figure 3.4 Roche: Market Forecast (\$bn), 2011-2022
- Figure 4.1 Amgen: Lead Biologics Share of Overall Revenues (%), 2011
- Figure 4.2 Drivers and Restraints for Amgen Biologics, 2012
- Figure 4.3 Amgen: Market Forecast (\$bn), 2011-2022
- Figure 4.4 Biogen Idec: Lead Biologics Share of Overall Revenues (%), 2011
- Figure 4.5 Biogen Idec: Drivers and Restraints, 2012
- Figure 4.6 Biogen Idec: Market Forecast (\$bn), 2011-2022
- Figure 4.7 CSL Behring: Regional Breakdown of Revenues (%), 2011
- Figure 4.8 CSL Behring: Lead Biologics Share of Revenues (%), 2011.
- Figure 4.9 Drivers and Restraints for CSL Biologics, 2012
- Figure 4.10 CSL Behring: Market Forecast (\$bn), 2011-2022
- Figure 4.11 Grifols: Breakdown of Revenues by Business Segment (%), 2011
- Figure 4.12 Grifols: Regional Distribution of Revenues (%), 2009-2011
- Figure 4.13 Grifols: Selected Biologics (\$bn), 2010
- Figure 4.14 Drivers and Restraints for Grifols Biologics, 2012
- Figure 4.15 Grifols: Market Forecast (\$bn), 2011-2022
- Figure 4.16 Allergan: Breakdown of Pharmaceutical Revenues (%), 2011
- Figure 4.17 Allergan: Geographical Breakdown of Revenues (%), 2011
- Figure 4.18 Drivers and Restraints for Allergan Biologics, 2012
- Figure 4.19 Allergan: Market Forecast (\$bn), 2011-2022
- Figure 5.1 Sanofi: Revenue Breakdown by Business Segment (%), 2011
- Figure 5.2 Sanofi: Leading Biologics, Share of Revenues (%), 2011
- Figure 5.3 Drivers and Restraints for Sanofi Biologics, 2012
- Figure 5.4 Sanofi: Market Forecast (\$bn), 2011-2022
- Figure 5.5 Pfizer: Leading Biologics, Share of Revenues (%), 2011
- Figure 5.6 Drivers and Restraints for Pfizer Biologics, 2012
- Figure 5.7 Pfizer: Market Forecast (\$bn), 2011-2022
- Figure 5.8 GlaxoSmithKline: Business Breakdown by Segment (%), 2011

- Figure 5.9 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
- Figure 5.10 GlaxoSmithKline: Market Forecast (\$bn), 2011-2022
- Figure 5.11 Leading Biologics, Share of Revenues (%), 2011
- Figure 5.12 Drivers and Restraints for Merck Biologics, 2012
- Figure 5.13 Merck: Market Forecast (\$bn), 2011-2022
- Figure 5.14 Leading Novartis Biologics, Share of Revenues (%), 2011
- Figure 5.15 Drivers and Restraints for Novartis Biologics, 2012
- Figure 5.16 Novartis: Market Forecast (\$bn), 2011-2022
- Figure 6.1 Novo Nordisk: Revenue Breakdown (%) by Business Segment, 2012
- Figure 6.2 Novo Nordisk Leading Biologics, Share of Revenues (%), 2011
- Figure 6.3 Drivers and Restraints for Novo Nordisk Biologics, 2012
- Figure 6.4 Novo Nordisk Market Forecast (\$bn), 2011-2022
- Figure 6.5 Merck KGaA Leading Biologics, Share of Revenues (%), 2011
- Figure 6.6 Drivers and Restraints for Merck KGaA, 2012
- Figure 6.7 Merck KGaA Biologics, Market Forecast (\$bn), 2011-2022
- Figure 6.8 Bayer: Distribution of Revenues by Business (%), 2011
- Figure 6.9 Bayer: Distribution of Revenues by Region (%), 2011
- Figure 6.10 Bayer Leading Biologics, Share of Revenues (%), 2011
- Figure 6.11 Drivers and Restraints for Bayer Biologics, 2012
- Figure 6.12 Bayer Biologics, Market Forecast (\$bn), 2011-2022
- Figure 6.13 AstraZeneca: Regional Distribution of Revenues (%), 2011
- Figure 6.14 AstraZeneca: Leading Biologics, Share of Total Revenues (%), 2011
- Figure 6.15 Drivers and Restraints for AstraZeneca Biologics, 2012
- Figure 6.16 AstraZeneca Biologics, Market Forecast (\$bn), 2011-2022
- Figure 7.1 Johnson & Johnson: Revenues Breakdown by Business Segment (%), 2012
- Figure 7.2 Johnson & Johnson: Leading Biologics, Share of Total Revenues (%), 2011
- Figure 7.3 Drivers and Restraints for Johnson & Johnson Biologics, 2012
- Figure 7.4 Johnson & Johnson Biologics, Market Forecast (\$bn), 2011-2022
- Figure 7.5 Abbott Laboratories: Revenue Breakdown by Business Segment (%), 2012
- Figure 7.6 Abbott: Leading Biologics, Share of Total Revenues (%), 2011
- Figure 7.7 Drivers and Restraints for Abbott, 2012
- Figure 7.8 Abbott Laboratories Biologics, Market Forecast (\$bn), 2011-2022
- Figure 7.9 Baxter: Breakdown of Revenues by Business (%), 2011
- Figure 7.10 Baxter: Breakdown of Revenues by Region (%), 2011
- Figure 7.11 Baxter: Share of Total Revenues (%), 2011
- Figure 7.12 Drivers and Restraints for Baxter Biologics, 2012
- Figure 7.13 Baxter Biologics, Market Forecast (\$bn), 2011-2022
- Figure 7.14 Eli Lilly: Breakdown of Pharmaceutical Sales by Therapeutic Area (%), 2011
- Figure 7.15 Eli Lilly: Leading Biologics, Share of Total Revenues (%), 2011

Figure 7.16 Drivers and Restraints for Eli Lilly Biologics, 2012

Figure 7.17 Eli Lilly Biologics, Market Forecast (\$bn), 2011-2022

Figure 7.18 Bristol-Myers Squibb: Regional Distribution of Revenues (%), 2011

Figure 7.19 Bristol-Myers Squibb: Leading Biologics, Share of Total Revenues (%), 2011

Figure 7.20 Drivers and Restraints for Bristol-Myers Squibb Biologics, 2012

Figure 7.21 Bristol-Myers Squibb Biologics, Market Forecast (\$bn), 2011-2022

COMPANIES LISTED

Abbott Laboratories

Abgenix

Ablynx

AC Immune

Acadia Pharmaceuticals

Acorda Therapeutics

Alantos Pharmaceuticals

ALK Abello

Allergan

Alnara Pharmaceuticals

Amgen

AstraZeneca

Avidia

Baxter International

Bayer HealthCare

Becton Dickinson

Biogen Idec

Bioheart

Biomira

BioVex

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

Cambridge Antibody Technologies

Centocor Ortho Biotech

Chinese Academy of Medical Sciences

Chinese Academy of Sciences

Chiron

Cilag Chemie

Coley Pharmaceuticals

Corixa
Cougar Biotechnology
CovX
Crucell Biotechnology
CSL Behring
CSL Biotherapies
CT Arzneimittel
Cytori
Dompé
Duke University
Dyax
Dynavax
Eisai
Elan
Eli Lilly
EMD Serono
Encysive Pharmaceuticals
ExonHit Therapeutics
Facet Biotech
Fresenius
F-Star
Galena Biopharma
Genentech
Genesis Pharma
Genetics Institute
Genmab
Genzyme
GlaxoSmithKline
GlycoFi
Grifols
GTC Biotherapeutics
HD Biosciences
Hexal
Hoechst Marion Roussel
Hospira
HudsonAlpha Institute for Biotechnology
Human Genome Sciences
Hutchison MediPharma
ID Biomedical

Ilypsa
ImClone
Immunex Corporation
ImmunoGen
Inspire Pharmaceuticals
Institute for Genomic Research
International Vaccine Institute
Ipsen
Janssen Pharmaceutica
Jiangsu Walvax Biotech Company
Johns Hopkins University
Johnson & Johnson
KAI Pharmaceuticals
Kinetix Pharmaceuticals
King
Knopp Neurosciences
Kuros
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Lipoxen
Ludwig Institute for Cancer Research
McNeil Laboratories
Medarex
MedImmune
Medixion
Megapharm
Merck & Co.
Merck BioVentures
Merck KGaA
Merck-Banyu
Merz Pharma
Micromet
Millipore
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mustafa Nevzat Pharmaceuticals
National Center for Drug Screening (China)
Nestlé

Neurimmune SubOne
Novartis
Novo Nordisk
Oncothyreon
Ortho Pharmaceutical
Oxford University
Pasteur Merieux Serums & Vaccins
PDL BioPharma
Peptech
Pfizer
Pharmacia
Philogen
Pieris
Piramal
Portola Pharmaceuticals
PowderMed
Protein Design
Regeneron
Roche
Sabin Vaccine Institute
Samsung Biologics
Sandoz
Sanofi
Sanofi Pasteur MSD
Sanwa Kagaku Kenkyusho
Schering-Plough
Senju Pharmaceutical
Serenex
Shanghai ChemExplorer
Shanghai Institute of Biological Sciences
Shanghai Institute of Materia Medica
Shantha Biotechnics
Sirna Therapeutics
Solvay Pharmaceuticals
Swedish Orphan Biovitrum
Synergen
Synovis Life Technologies
Syntonix
Takeda

Talecris
Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital
Transkaryotic Therapies
Trellis Bioscience
Trubion
Tularik
University of Queensland
Upjohn
Vaxdesign
Vernalis
VIVALis
Walter Reed Army Institute
Warner-Lambert
World Health Organization (WHO)
WuXi AppTec
Wyeth Pharmaceuticals
Zhejiang Taiyuan
Zydus Cadila
ZymoGenetics

I would like to order

Product name: Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022

Product link: <https://marketpublishers.com/r/P263B37C73CEN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P263B37C73CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970